{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056996","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.878975+00:00","generated_at":"2026-05-19T18:22:05.160143+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039","bullets":["Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).","Eugia granted royalty-free license to market generic version on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation continues against two other ANDA filers: Cipla and Mankind Pharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056996","json":"https://secwatch.observer/filing/0001104659-25-056996.json","markdown":"https://secwatch.observer/filing/0001104659-25-056996.md","text":"https://secwatch.observer/filing/0001104659-25-056996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925056996/0001104659-25-056996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925056996/tm2517353d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:22:05.160143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}